ESPE Abstracts

Achondroplasia (ACH) is the most common human skeletal dysplasia caused by gain -of-function mutation in the fibroblast growth factor receptor gene (FGFR) 3-encoding protein. Vosoritide, an analog of C-type natriuretic peptide (CNP), is currently the sole medication approved for ACH treatment. Vosoritide can only be administered by daily injection, leaving room for improvement. Infigratinib, a pan-FGFR1/2/3 inhibitor, offers a potential oral treatment alternative and is curren...